218 related articles for article (PubMed ID: 35412602)
1. Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease.
Xu YT; Zhang YM; Yang HX; Ye LF; Chen F; Lu X; Wang GC; Peng QL
Rheumatology (Oxford); 2022 Dec; 62(1):397-406. PubMed ID: 35412602
[TBL] [Abstract][Full Text] [Related]
2. Distribution of anti-melanoma differentiation associated gene 5 (MDA5) IgG subclasses in MDA5+ dermatomyositis.
Chen M; Zhao Q; Diao L; Xue K; Ruan Y; Xue F; Li J; Shi R; Pan M; Zheng J; Cao H
Rheumatology (Oxford); 2021 Dec; 61(1):430-439. PubMed ID: 33742662
[TBL] [Abstract][Full Text] [Related]
3. Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease.
Li X; Liu Y; Cheng L; Huang Y; Yan S; Li H; Zhan H; Li Y
J Clin Lab Anal; 2022 Nov; 36(11):e24726. PubMed ID: 36221983
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
5. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis.
Shi Y; You H; Liu C; Qiu Y; Lv C; Zhu Y; Xu L; Wang F; Zhang M; Tan W
Orphanet J Rare Dis; 2024 Apr; 19(1):170. PubMed ID: 38637830
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease.
Ren FP; Chen Q; Yao SS; Feng L; Xue XY; Zhao WC; Wang D; Zhao ZL; Gu SW; Li T; Shen YW; Gao L; Zang XL; Bao XY; Tong ZH
BMC Pulm Med; 2023 Oct; 23(1):411. PubMed ID: 37898737
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Role of Interferon-λ3 in Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis-Associated Interstitial Lung Disease.
Fukada A; Fujisawa T; Hozumi H; Koda K; Akamatsu T; Oyama Y; Satake Y; Niwa M; Kaida Y; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Hashimoto D; Yoshida A; Gono T; Kuwana M; Yamano Y; Kondoh Y; Yamashita K; Maekawa M; Mori K; Inoue Y; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Inui N; Suda T
Arthritis Rheumatol; 2024 May; 76(5):796-805. PubMed ID: 38146102
[TBL] [Abstract][Full Text] [Related]
9. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
10. Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model.
Wang L; Lv C; You H; Xu L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Liu J; Wang F; Zhang M; Tan W
Front Immunol; 2024; 15():1286973. PubMed ID: 38361940
[TBL] [Abstract][Full Text] [Related]
11. Prognostic evaluation of serum osteopontin in patients with anti-MDA5 antibody-positive dermatomyositis associated interstitial lung disease.
Gao Y; Zhao Q; Xie M; Yan X; Li Y; Zhang X; Wu H; Dai J; Cao M; Cai H
Cytokine; 2020 Nov; 135():155209. PubMed ID: 32738770
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody-Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk.
Lv C; You H; Xu L; Wang L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Wang F; Zhang M; Tan W
J Rheumatol; 2023 Feb; 50(2):219-226. PubMed ID: 35705235
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
14. Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis.
Qiu Y; Feng X; Liu C; Shi Y; Xu L; You H; Wang L; Lv C; Wang F; Tan W
Arthritis Res Ther; 2024 Jan; 26(1):9. PubMed ID: 38167532
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis.
Gui X; Ma M; Ding J; Shi S; Xin X; Qiu X; Zhang Y; Qiu Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
Rheumatology (Oxford); 2021 Aug; 60(8):3913-3922. PubMed ID: 33501503
[TBL] [Abstract][Full Text] [Related]
16. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
Horiike Y; Suzuki Y; Fujisawa T; Yasui H; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Ogawa N; Suda T
Rheumatology (Oxford); 2019 Dec; 58(12):2143-2152. PubMed ID: 31143953
[TBL] [Abstract][Full Text] [Related]
17. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
Front Immunol; 2022; 13():845988. PubMed ID: 35320936
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti-MDA5 antibody-positive dermatomyositis related interstitial lung disease.
Li Y; Liu X; Tian M; Zou R; Gao Y; Huang M; Zhou K; Cao M; Cai H
Clin Respir J; 2023 Jun; 17(6):507-515. PubMed ID: 37041007
[TBL] [Abstract][Full Text] [Related]
19. Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease.
Zhu Y; Wang L; Sun Y; Wang J; Lv C; You H; Xu L; Wang F; Zhang M; Tan W; Ke Y
Clin Exp Rheumatol; 2022 Feb; 40(2):292-297. PubMed ID: 34874831
[TBL] [Abstract][Full Text] [Related]
20. Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease.
Harada H; Shoda H; Tsuchiya H; Misaki M; Sawada T; Fujio K
Rheumatol Int; 2024 May; 44(5):961-971. PubMed ID: 38456909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
